Market Trends of Hospital Infection Therapeutics Industry
The Antibacterial Drugs Segment is Expected to Witness Significant Growth Over the Forecast Period
Antibacterial drugs are chemical agents which suppress growth and multiplication and kill bacteria. Antibacterial drugs have an essential application in controlling and curing bacterial infections acquired at hospitals. The high volume of hospital-acquired bacterial infections is expected to create a high demand for antibacterial drugs to curb the infections. For instance, as per the data published by the United States Department of Health & Human Services in November 2022, over 3,774 cases of catheter-associated urinary tract infections were reported by acute care hospitals in the United States in 2021.
Furthermore, several studies have highlighted the high burden of HAIs and the use of antibacterials for their effective management. Further, a study published in the International Journal of Environmental Research and Public Health in December 2021 highlighted the increased use of antibiotic and antibacterial drugs, such as Ceftriaxone, Piperacillin, Metronidazole, and others, in the public hospitals of Makkah, Saudi Arabia. Antibiotics and antibacterial drugs were administered to the patients to control HAIs such as pneumonia, cardiovascular system and prophylactic gastrointestinal tract infections, and others. Thus, the high prevalence of hospital-acquired bacterial infections and the massive use of antibacterial for their management are expected to boost the demand for antibacterial drugs globally.
Furthermore, the recent launches by the market players in the area of antibacterial drugs would further strengthen the growth of the segment. For instance, in March 2023, Glenmark Pharmaceuticals received approval from the USFDA to market a generic antibiotic drug, Clindamycin Hydrochloride capsules. The drug is the generic version of Pfizer's Cleocin capsules and is intended for the management of a variety of infections. Further, in September 2021, BDR Pharma launched its drug BIAPENEM, which is a carbapenem antibacterial agent intended to treat urinary tract infections.
Therefore, the antibacterial drugs segment is expected to witness significant growth over the forecast period due to the abovementioned factors, including its vast applications to curb bacterial infections acquired at hospitals.
North America is Expected to Witness Significant Growth Over the Forecast Period
North America is expected to witness significant growth over the forecast period, owing to factors such as the high prevalence of HAIs, high volume of hospitalizations and surgery, expanding geriatric population, advanced medical expenditure, and infrastructure. The region has a high prevalence of HAIs, which is expected to drive the demand for hospital infection therapeutics. For instance, as per the data published by the United States Department of Health & Human Services in November 2022, 30,389 cases of catheter line-associated bloodstream infections were recorded in acute care hospitals in the United States in 2021. The same source stated that over 1,995 cases of ventilator-associated infections were reported by acute care hospitals in the United States in 2021.
Furthermore, the region has a high volume of surgeries, which also increases the risk of contracting HAIs, and this increases the demand for hospital infection therapeutics in the region. For instance, data published by the Canadian Institute for Health Information (CIHI) in June 2022 states that over 110,000 procedures of joint replacements were performed in 2020-2021, and more than 7,300 procedures were performed as day surgeries.
Also, the key developments by the market players in the region are expected to boost the growth of the market. For instance, in December 2022, Innoviva, Inc. received acceptance from the USFDA for the Priority Review of the new drug application for its SUL-DUR. The NDA submission is based on results from the landmark phase 3 ATTACK trial evaluating the safety and efficacy of SUL-DUR in patients with ABS infection in hospital-acquired pneumonia, ventilated pneumonia or bacteremia, ventilator-associated bacterial pneumonia, and other patients. Further, in March 2022, Cumberland Pharmaceuticals Inc. and Verity Pharmaceuticals International Ltd. today launched Cumberland's VIBATIV (telavancin) injection in Puerto Rico, the United States. The drug injection is intended for the management of hospital-acquired and ventilator-associated pneumonia.
Therefore, owing to the aforementioned factors, including the high prevalence of HAIs and the high volume of surgeries, the growth of the studied market is anticipated in the North American region.
